Genetic Polymorphisms of IL-17F and TRAF3IP2 Could Be Predictive Factors of the Long-Term Effect of Infliximab against Crohn’s Disease

Table 3

Allele and genotype comparisons in three inheritance models between responders and nonresponders to IFX after 1 year of treatment of CD patients.

Gene symbol	Tag SNP; (Major > minor)	Genotype	Number of genotypes (%)		Inheritance model	value	OR	95% CI
			Responders	Nonresponders
			= 89	= 14
IL17A	rs4711998; A > G	MAF	0.337	0.321	Allele	0.870	1.073	0.458–2.517
		A/A	39 (43.8)	6 (42.9)
		A/G	40 (44.9)	7 (50.0)	Dominant	0.946	0.962	0.308–3.002
		G/G	10 (11.2)	1 (7.1)	Recessive	1.000	1.646	0.194–13.96
	rs8193036; C > T	MAF	0.438	0.393	Allele	0.653	1.205	0.534–2.722
		C/C	32 (36.0)	5 (35.7)
		C/T	36 (40.4)	7 (50.0)	Dominant	1.000	0.990	0.305–3.208
		T/T	21 (23.6)	2 (14.3)	Recessive	0.730	1.853	0.384–8.954
	rs3819024; G > A	MAF	0.421	0.423	Allele	0.669	0.840	0.377–1.870
		G/G	33 (37.1)	5 (35.7)
		G/A	37 (41.6)	5 (35.7)	Dominant	1.000	0.943	0.291–3.053
		A/A	19 (21.3)	4 (28.6)	Recessive	0.509	0.679	0.191–2.406
	rs2275913; G > A	MAF	0.343	0.393	Allele	0.605	0.806	0.355–1.828
		G/G	40 (44.9)	5 (35.7)
		G/A	37 (41.6)	7 (50.0)	Dominant	0.575	0.681	0.211–2.194
		A/A	12 (13.5)	2 (14.3)	Recessive	1.000	0.935	0.186–4.707
	rs3819025; G > A	MAF	0.292	0.321	Allele	0.752	0.871	0.370–2.052
		G/G	47 (52.8)	7 (50.0)
		G/A	32 (36.0)	5 (35.7)	Dominant	0.845	0.894	0.289–2.760
		A/A	10 (11.2)	2 (14.3)	Recessive	0.666	0.759	0.148–3.897
IL17F	rs763780; T > C	MAF	0.157	0.071	Allele	0.385	2.427	0.545–10.81
		T/T	63 (70.8)	12 (85.7)
		T/C	24 (27.0)	2 (14.3)	Dominant	0.341	2.476	0.518–11.85
		C/C	2 (2.2)	0 (0)	Recessive	1.000	0.829	0.038–18.17
	rs766748; G > A	MAF	0.247	0.429	Allele	0.045	0.438	0.192–0.997
		G/G	51 (57.3)	3 (21.4)
		G/A	32 (36.0)	10 (71.4)	Dominant	0.019	0.203	0.053–0.779
		A/A	6 (6.7)	1 (7.1)	Recessive	1.000	0.940	0.105–8.454
	rs12201582; C > A	MAF	0.112	0.143	Allele	0.750	0.760	0.239–2.414
		C/C	70 (78.7)	10 (71.4)
		C/A	18 (20.2)	4 (28.6)	Dominant	0.509	0.679	0.191–2.406
		A/A	1 (1.1)	0 (0)	Recessive	1.000	0.554	0.021–14.29
	rs9382084; T > G	MAF	0.433	0.357	Allele	0.453	1.372	0.600–3.141
		T/T	34 (38.2)	4 (28.6)
		T/G	33 (37.1)	10 (71.4)	Dominant	0.564	0.647	0.188–2.227
		G/G	22 (24.7)	0 (0)	Recessive	0.037	9.671	0.554–168.8
	rs722323; C > T	MAF	0.438	0.429	Allele	0.924	1.040	0.465–2.326
		C/C	31 (34.8)	4 (28.6)
		C/T	38 (42.7)	8 (57.1)	Dominant	0.768	0.748	0.217–2.584
		T/T	20 (22.5)	2 (14.3)	Recessive	0.729	1.739	0.359–8.425
	rs1266828; T > C	MAF	0.146	0.143	Allele	1.000	1.026	0.329–3.201
		T/T	66 (74.2)	10 (71.4)
		T/C	20 (22.5)	4 (28.6)	Dominant	0.757	0.871	0.249–3.051
		C/C	3 (3.4)	0 (0)	Recessive	1.000	1.173	0.058–23.94
	rs2294834; A > C	MAF	0.157	0.179	Allele	0.783	0.859	0.301–2.449
		A/A	65 (73.0)	9 (64.3)
		A/C	20 (22.5)	5 (35.7)	Dominant	0.530	0.665	0.202–2.184
		C/C	4 (4.5)	0 (0)	Recessive	1.000	1.526	0.078–29.90
IL17RA	rs2270241; T > G	MAF	0.365	0.429	Allele	0.519	0.767	0.342–1.721
		T/T	34 (38.2)	5 (35.7)
		T/G	45 (50.6)	6 (42.9)	Dominant	1.000	0.899	0.278–2.908
		G/G	10 (11.2)	3 (21.4)	Recessive	0.379	0.464	0.110–1.952
	rs2241042; A > C	MAF	0.225	0.286	Allele	0.478	0.725	0.297–1.769
		A/A	52 (58.4)	6 (42.9)
		A/C	34 (38.2)	8 (57.1)	Dominant	0.275	0.534	0.171–1.668
		C/C	3 (3.4)	0 (0)	Recessive	1.000	1.173	0.058–23.94
	rs5748864; G > A	MAF	0.478	0.536	Allele	0.567	0.792	0.356–1.761
		G/G	24 (27.0)	3 (21.4)
		G/A	45 (50.6)	7 (50.0)	Dominant	0.757	0.739	0.190–2.878
		A/A	20 (22.5)	4 (28.6)	Recessive	0.734	0.725	0.205–2.560
	rs2241044; A > C	MAF	0.292	0.357	Allele	0.486	0.743	0.321–1.717
		A/A	43 (48.3)	5 (35.7)
		A/C	40 (44.9)	8 (57.1)	Dominant	0.407	0.594	0.185–1.915
		C/C	6 (6.7)	1 (7.1)	Recessive	1.000	0.940	0.105–8.454
	rs2241049; A > G	MAF	0.326	0.429	Allele	0.286	0.644	0.286–1.451
		A/A	43 (48.3)	6 (42.9)
		A/G	34 (38.2)	4 (28.6)	Dominant	0.704	0.802	0.257–2.502
		G/G	12 (13.5)	4 (28.6)	Recessive	0.225	0.390	0.105–1.444
	rs2229151; G > A	MAF	0.287	0.321	Allele	0.706	0.849	0.360–1.998
		G/G	44 (49.4)	7 (50.0)
		G/A	39 (43.8)	5 (35.7)	Dominant	0.969	1.023	0.331–3.158
		A/A	6 (6.7)	2 (14.3)	Recessive	0.297	0.434	0.078–2.401
	rs2895332; A > G	MAF	0.348	0.286	Allele	0.517	1.336	0.556–3.209
		A/A	37 (41.6)	6 (42.9)
		A/G	42 (47.2)	8 (57.1)	Dominant	0.928	1.054	0.337–3.295
		G/G	10 (11.2)	0 (0)	Recessive	0.350	3.830	0.212–69.09
IL17RC	rs7627880; G > A	MAF	0.112	0	Allele	0.082	7.372	0.433–125.5
		G/G	71 (79.8)	14 (100)
		G/A	16 (18.0)	0 (0)	Dominant	0.122	7.503	0.427–131.8
		A/A	2 (2.2)	0 (0)	Recessive	1.000	0.829	0.038–18.17
	rs279545; A > G	MAF	0.213	0.179	Allele	0.806	1.249	0.445–3.503
		A/A	55 (61.8)	9 (64.3)
		A/G	30 (33.7)	5 (35.7)	Dominant	1.000	1.113	0.344–3.600
		G/G	4 (4.5)	0 (0)	Recessive	1.000	1.526	0.078–29.90
TRAF3IP2	rs6941014; T > C	MAF	0.365	0.500	Allele	0.173	0.575	0.258–1.282
		T/T	35 (39.3)	4 (28.6)
		T/C	43 (48.3)	6 (42.9)	Dominant	0.560	0.617	0.179–2.123
		C/C	11 (12.4)	4 (28.6)	Recessive	0.120	0.353	0.094–1.321
	rs1883136; C > A	MAF	0.292	0.464	Allele	0.068	0.476	0.212–1.071
		C/C	44 (49.4)	5 (35.7)
		C/A	38 (42.7)	5 (35.7)	Dominant	0.398	0.568	0.176–1.830
		A/A	7 (7.9)	4 (28.6)	Recessive	0.041	0.213	0.053–0.860
	rs1040383; C > G	MAF	0.528	0.357	Allele	0.257	1.609	0.703–3.679
		C/C	24 (27.0)	6 (42.9)
		C/G	46 (51.7)	6 (42.9)	Dominant	0.224	2.031	0.638–6.465
		G/G	19 (21.3)	2 (14.3)	Recessive	0.729	1.629	0.335–7.914
	rs9374263; G > C	MAF	0.331	0.429	Allele	0.315	0.661	0.294–1.488
		G/G	40 (44.9)	6 (42.9)
		G/C	39 (43.8)	4 (28.6)	Dominant	0.884	0.919	0.294–2.868
		C/C	10 (11.2)	4 (28.6)	Recessive	0.096	0.317	0.083–1.201

Allele: allele model; Dominant: the minor allele dominant model; Recessive: the minor allele recessive model.
IFX: infliximab; CD: Crohn’s disease; SNP: single nucleotide polymorphism; MAF: minor allele frequency; OR: odds ratio; CI: confidence interval.